The immunohistochemistry market faces competition from a range of alternative diagnostic techniques, including molecular diagnostics, flow cytometry, and next-generation sequencing. These techniques offer advantages over IHC in terms of speed, sensitivity, and the ability to analyze multiple targets simultaneously. While IHC remains an important diagnostic tool, it may be losing market share to these alternative techniques in certain applications. The limited availability of skilled pathologists is another factor that is hampering the growth of the Immunohistochemistry Market. The interpretation of IHC results requires specialized training and expertise, and there is a shortage of pathologists with this level of training in many regions of the world. This can lead to delays in diagnosis, misinterpretation of results, and variability in the quality of results across different laboratories.
The interpretation of IHC results is subjective and can be influenced by a number of factors, including the experience and training of the pathologist, the quality of the tissue sample, and the quality of the reagents used. In addition, the lack of standardization in the use of IHC assays can lead to variability in results and limit the comparability of results across different laboratories and studies.
One of the major factors hampering the growth of the immunohistochemistry market is the limited awareness and adoption of IHC techniques. Despite the many advantages of IHC, including its high specificity and sensitivity, many healthcare professionals are not familiar with the technique and may not be aware of its potential applications. Additionally, there is a lack of standardization in the use of IHC, which can lead to variability in results and limit its widespread adoption.
Read more @ https://influentialblogging.blogspot.com/2023/05/global-immunohistochemistry-market-is.html
The global immunohistochemistry market size is expected to reach a value of USD 3.2 billion by 2027, expanding at a CAGR of 7.8%, according to a new report by Radiant Insights, Inc.
IHC has become a crucial technique and is widely applied in the diagnosis of several chronic diseases such as cancer, infectious diseases, and cardiovascular diseases (CVDs).
Thus, a rise in the incidence of these chronic diseases has led to an increase in the demand for IHC techniques.
According to 2018 data published by WHO, globally, cancer was one of the leading causes of mortality, and in 2018 around 9.6 million deaths were registered due to cancer.
Additionally, in June 2019, the U.S. FDA approved the expanded use of Agilent Technologies’ PD-L1 IHC 22C3 pharmDx assay for the detection of head and neck squamous cell carcinoma (HNSCC).
This product is used in patients receiving treatment with Merck and Co., Inc.’s Keytruda (Pembrolizumab).
